



10/509078

INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

REC'D 30 JUN 2003

WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it was re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Andrew Gense

Dated 2 April 2003

BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry

The
Patent
Office


12/1/77 03/03/97
12.06.02

1/77

28MAR02 E707187-1 C69803
P01/7700 0.00-0207289.0

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

2. Patent application number
(The Patent Office will fill in his part)

0207289.0

27 MAR 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Glaxo Group Limited
Glaxo Wellcome House, Berkeley Avenue,
Greenford, Middlesex UB6 0NN, Great Britain

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

United Kingdom

473587003

4. Title of the invention

Novel Compounds

5. Name of your agent (if you have one)

Corporate Intellectual Property

"Address for service" in the United Kingdom to which all correspondence should be sent
(including the postcode)

GlaxoSmithKline
Corporate Intellectual Property CN925.1
980 Great West Road
BRENTFORD
Middlesex TW8 9GS

Patents ADP number (if you know it)

796982003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)
---------	---	--

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing (day / month / year)
-------------------------------	--

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if:


- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is named as an applicant, or
 - c) any named applicant is a corporate body
- See note (d)

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form
Description
Claim(s)
Abstract
Drawings

9
2



10. If you are also filing any of the following,
state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination
and search (*Patents Form 9/77*)


Request for substantive examination
(*Patents Form 10/77*)

Any other documents
(*please specify*)

11.

We request the grant of a patent on the basis of this

application

Signature  Date 27-Mar-02

S C Hockley

12. Name and daytime telephone number of
person to contact in the United Kingdom

S C Hockley 01279 644355

Warning

After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- a) *If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- b) *Write your answers in capital letters using black ink or you may type them.*
- c) *If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- d) *If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- f) *For details of the fee and ways to pay please contact the Patent Office.*

NOVEL COMPOUNDS

This invention relates to novel quinoline compounds having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of CNS and other disorders.

WO 98/27081 discloses a series of aryl sulphonamide compounds that are said to be 5-HT₆ receptor antagonists and which are claimed to be useful in the treatment of various CNS disorders. GB-2341549, WO 99/47516 and WO 99/65906 all disclose a series of indole derivatives that are claimed to 5-HT₆ receptor affinity. JP 02262627 (Japan Synthetic Rubber Co) describes a series of substituted quinoline derivatives useful as wavelength converting elements. WO 00/42026 (Novo Nordisk) describes a series of quinoline and quinoxaline compounds for use as GLP-1 agonists.

A structurally novel class of compounds has now been found which also possess affinity for the 5-HT₆ receptor. The present invention therefore provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ and R² independently represent hydrogen or C₁₋₆ alkyl or R¹ is linked to R² to form a group (CH₂)₂, (CH₂)₃ or (CH₂)₄;

R³, R⁴ and R⁵ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

m represents an integer from 1 to 4, when m is an integer greater than 1, two R² groups may instead be linked to form a group CH₂, (CH₂)₂ or (CH₂)₃;

n represents an integer from 1 to 3;

p represents 1 or 2;

A represents a group -Ar¹ or -Ar²Ar³;

- Ar¹, Ar² and Ar³ independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆ alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group CONR⁸R⁹ or SO₂NR⁸R⁹, wherein R⁸ and R⁹ independently represent hydrogen or C₁₋₆ alkyl or together may be fused to form a 5- to 7-membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; or solvates thereof.
- 15 Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C₁₋₄ alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.
- 20 The term "aryl" includes phenyl and naphthyl.

The term "heteroaryl" is intended to mean a 5-7 membered monocyclic aromatic or a fused 8-10 membered bicyclic aromatic ring containing 1 to 3 heteroatoms selected from oxygen, nitrogen and sulphur. Suitable examples of such monocyclic aromatic rings include thienyl, furyl, 25 aryl, triazolyl, imidazolyl, oxazolyl, thiazolyl, oxadiazolyl, isothiazolyl, isoxazolyl, thiadiazolyl, pyrazolyl, pyrimidyl, pyridazinyl, pyrazinyl and pyridyl. Suitable examples of such fused aromatic rings include benzofused aromatic rings such as quinolinyl, isoquinolinyl, quinazolinyl, quinoxalinyl, cinnolinyl, naphthyridinyl, indolyl, indazolyl, pyrrolopyridinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, 30 benzisothiazolyl, benzoxadiazolyl, benzothiadiazolyl and the like. Heteroaryl groups, as described above, may be linked to the remainder of the molecule via a carbon atom or, when present, a suitable nitrogen atom except where otherwise indicated above.

35 It will be appreciated that wherein the above mentioned aryl or heteroaryl groups have more than one substituent, said substituents may be linked to form a ring, for example a carboxyl and amine group may be linked to form an amide group.

Preferably, R¹ represents hydrogen or methyl.

Preferably R² represents hydrogen.

40 Preferably R³ represents hydrogen or halogen, especially hydrogen.

Preferably R⁴ and R⁵ independently represent hydrogen or methyl, especially hydrogen.

Preferably m, n and p all represent 1.

When A represents a group $-Ar^1$, Ar^1 preferably represents optionally substituted phenyl or pyridyl, more preferably phenyl optionally substituted with halogen, cyano, trifluoromethyl or trifluoromethoxy. Particularly preferred Ar^1 is unsubstituted phenyl.

When A represents a group $-Ar^2-Ar^3$, Ar^2 and Ar^3 preferably both independently represent phenyl or monocyclic heteroaryl group as defined above.

Preferably A represents a group $-Ar^1$.

Preferred compounds according to the invention include examples E1-E2 as shown below, or a pharmaceutically acceptable salt thereof.


The compounds of formula (I) can form acid addition salts thereof. It will be appreciated that for use in medicine the salts of the compounds of formula (I) should be pharmaceutically acceptable. Suitable pharmaceutically acceptable salts will be apparent to those skilled in the art and include those described in J. Pharm. Sci., 1977, 66, 1-19, such as acid addition salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids e.g. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.

The compounds of formula (I) may be prepared in crystalline or non-crystalline form, and, if crystalline, may optionally be solvated, eg. as the hydrate. This invention includes within its scope stoichiometric solvates (eg. hydrates) as well as compounds containing variable amounts of solvent (eg. water).

Certain compounds of formula (I) are capable of existing in stereoisomeric forms (e.g. diastereomers and enantiomers) and the invention extends to each of these stereoisomeric forms and to mixtures thereof including racemates. The different stereoisomeric forms may be separated one from the other by the usual methods, or any given isomer may be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.

The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

wherein R^{1a} is as defined for R^1 or an *N*-protecting group, R^2 , R^3 , R^4 , R^5 , m , n and p are as defined above and L^1 is a leaving group such as iodo or trifluoromethylsulfonyloxy;
 5 with a compound of formula $A-SO_2H$, (or $A-SH$ followed by a subsequent oxidation step) wherein A is as defined above and thereafter as necessary removing an R^{1a} *N*-protecting group;

(b) deprotecting a compound of formula (I) which is protected; and thereafter optionally

10 (c) interconversion to other compounds of formula (I) and/or forming a pharmaceutically acceptable salt and/or solvate.

The *N*-protecting group used may be any conventional group e.g. *t*-butoxycarbonyl (Boc) or benzyloxycarbonyl:

15 Process (a) wherein a compound of formula (I) is reacted with a compound of formula $A-SO_2H$ typically comprises use of basic conditions and may be conveniently carried out by using a suitable salt of the compound $A-SO_2H$ (e.g. the sodium salt) in an appropriate solvent such as *N,N*-dimethylformamide, in the presence of a transition metal salt such as copper (I) iodide.


20 Process (a) wherein a compound of formula (II) is reacted with a compound of formula $A-SH$ typically comprises use of basic conditions e.g. by using a suitable salt of the compound $A-SH$ (e.g. the sodium salt) in an appropriate solvent such as *N,N*-dimethylformamide, in the presence of a suitable metal salt such as copper (I) iodide, followed by use of a suitable oxidant such as 3-chloroperbenzoic acid, peracetic acid or potassium monopersulfate.

25 In processes (a) and (b), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or *t*-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl ($-COCF_3$) which may be removed by base catalysed hydrolysis or a solid phase


resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid. A further amine protecting group includes methyl which may be removed using standard methods for N-dealkylation (e.g. 1-chloroethyl chloroformate under basic conditions followed by treatment with methanol).

Process (c) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation. For example, N-dealkylation of a compound of formula (I) wherein R¹ represents an alkyl group to give a compound of formula (I) wherein R¹ represents hydrogen. It will be appreciated that such interconversion may be interconversion of protected derivatives of formula (I) which may subsequently be deprotected following interconversion.

Compounds of formula (II) may be prepared by reacting a compound of formula (III)



with a compound of formula (IV)



wherein R^{1a}, R², R³, R⁴, R⁵, m, n and p are as defined above, and L² represents a suitable leaving group, such as a halogen atom. This process typically comprises the use of a suitable base, such as sodium carbonate and the use of a suitable solvent such as *n*-butanol.

Compounds of formula (III) and (IV) are known in the literature or can be prepared by analogous methods.

Pharmaceutically acceptable salts may be prepared conventionally by reaction with the appropriate acid or acid derivative.

Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for the 5-HT₆ receptor and are believed to be of potential use in the treatment of certain CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, cognitive memory disorders (e.g. Alzheimers disease, age related cognitive decline and mild cognitive impairment),

Parkinsons Disease, ADHD (Attention Deficit Disorder/Hyperactivity Syndrome), sleep disorders (including disturbances of Circadian rhythm), feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome). Compounds of the invention are also expected to be of use in the treatment of obesity.

Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance, in particular in the treatment or prophylaxis of the above disorders. In particular the invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of depression, anxiety, obesity and cognitive memory disorders

The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment or prophylaxis of the above disorders.

In order to use the compounds of formula (I) in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice. The present invention also provides a pharmaceutical composition, which comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusable solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles

133027

(which may include edible oils), preservatives, and, if desired, conventional flavourings or colourants.

5 For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration.

20 The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 0.05 to 200 mg, for example 20 to 40 mg; and such unit doses will preferably be administered once a day, although administration more than once a day may be required; and such therapy may extend for a number of weeks or months.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

30 The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1

35 **3-Bromo-8-(4-methyl-piperazin-1-yl)-quinoline (D1)**

bis-(2-Chloro-ethyl)-amine hydrochloride (3.7g, 19.2mmol) and sodium carbonate (9.0g, 85mmol) were added to a suspension of 3-bromo-quinolin-8-ylamine (3.9g, 17.5mmol) (for synthesis see Gershon *et al.*, *Monatsh. Chem.*, 1991, 122, 935) in *n*-butanol (70ml). The stirred suspension was heated at reflux for 72h. The reaction mixture was cooled to ambient temperature, diluted with dichloromethane (300ml) and the solution washed with water (300ml), dried (MgSO₄) and concentrated *in vacuo* to an oil. The oil was purified by chromatography over silica gel eluting with a gradient of methanol/dichloromethane to afford the title compound (D1) as an oil (2.6g, 8.5mmol, 49%).

δ_H (CDCl₃) 2.43 (3H, s), 2.78 (4H, br s), 3.44 (4H, br, s), 7.14 (1H, d, J = 6.8Hz), 7.33 (1H, d, J = 7.4Hz), 7.47 (1H, dd, J = 7.8Hz), 8.25 (1H, d, J = 2.3Hz), 8.85 (1H, d, J = 2.3Hz).

Mass Spectrum : C₁₄H₁₆BrN₃ requires 305/307; found 306/308 (MH⁺).

5 Description 2

3-Iodo-8-(4-methyl-piperazin-1-yl)-quinoline (D2)

A mixture of 3-bromo-8-(4-methyl-piperazin-1-yl)-quinoline (D1)(1.75g, 5.7mmol), copper (I) iodide (5.4g, 28.5mmol) and potassium iodide (9.6g, 57.8mmol) in hexamethylphosphoramide (20ml) was heated in an oil bath at 150°C for 21h under argon. To the cooled reaction mixture was added toluene (120ml) and 1M hydrochloric acid (120ml) and the whole was shaken vigorously for 5 minutes. The insoluble brown solid was then collected by filtration, washed with methanol (3 x 40ml) and resuspended in a mixture of dichloromethane (150ml) and 2M sodium hydroxide (150ml). After shaking the mixture vigorously, the insoluble material was filtered, washed with dichloromethane (2 x 50ml) and discarded. The filtrate and washings were transferred to a separating funnel and the layers were separated. The aqueous phase was extracted with dichloromethane (2 x 100ml) and the combined organic extracts were dried (MgSO₄) and concentrated to a brown oil (1.5g) which was identified by NMR spectroscopy as a mixture of the title compound (D2) and 3-bromo-8-(4-methyl-piperazin-1-yl)-quinoline (D1) in a ratio of 4:1. This mixture was used directly in the next stage (see Example 1).

3-Iodo-8-(4-methyl-piperazin-1-yl)-quinoline (D2): δ_H (CDCl₃) 2.41 (3H, s), 2.76 (4H, br s), 3.42 (4H, br s), 7.14 (1H, d, J = 6.8Hz), 7.29 (1H, d, J = 7.4Hz), 7.47 (1H, dd, J = 7.8Hz), 8.47 (1H, d, J = 2.3Hz), 8.98 (1H, d, J = 2.3Hz).

Mass Spectrum : C₁₄H₁₆IN₃ requires 353; found 354 (MH⁺).

25

Example 1

8-(4-Methyl-piperazin-1-yl)-3-phenylsulfonylquinoline (E1)


A 4:1 mixture of 3-iodo-8-(4-methyl-piperazin-1-yl)-quinoline (D2) and 3-bromo-8-(4-methyl-piperazin-1-yl)-quinoline (D1) (1.5g), phenylsulfinic acid sodium salt, dihydrate (2.52g, 12.6mmol) and copper (I) iodide (2.4g, 12.6mmol) in *N,N*-dimethylformamide (25ml) was stirred in an oil bath at 120°C for 40h under argon. To the reaction mixture, cooled to ambient temperature, was added 5% sodium hydrogen carbonate solution (100ml) and dichloromethane (100ml) with vigorous shaking. The insoluble material was filtered, washed with dichloromethane (3 x 20ml) and discarded. The filtrate and washings were transferred to a separating funnel and the layers separated. The aqueous layer was extracted with dichloromethane (100ml) and the combined organic extracts were washed with water (100ml), dried (MgSO₄) and concentrated *in vacuo* to an oil (0.9g). The oil was purified by chromatography over silica gel eluting with a gradient of methanol/dichloromethane to afford an orange oil (0.28g, R_f 0.11, methanol/dichloromethane 1:19). This material was further purified by passage through a strong cation exchange (SCX) column eluting firstly with methanol (fractions discarded) and then with methanol/aqueous ammonia-880 (10:1) to give the title compound (E1) as an orange oil (0.152g, 0.41mmol, 7% over two steps).

δ_H (CDCl₃) 2.40 (3H, s), 2.72-2.76 (4H, m), 3.44 (4H, br, s), 7.25-7.27 (1H, m), 7.48-7.61 (5H, m), 7.99-8.02 (2H, m), 8.75 (1H, d, $J = 2.4\text{Hz}$), 9.21 (1H, d, $J = 2.4\text{Hz}$).

Mass Spectrum : C₂₀H₂₁N₃O₂S requires 367; found 368 (MH⁺).

5 Example 2

3-Phenylsulfonyl-8-piperazin-1-yl-quinoline hydrochloride (E2)



- A stirred solution of 8-(4-methyl-piperazin-1-yl)-3-phenylsulfonylquinoline (E1) (0.148g, 0.4mmol), 1-chloroethyl chloroformate (0.093ml, 0.85mmol) and N,N-diisopropylethylamine (0.148ml, 0.85mmol) in 1,2-dichloroethane (9ml) was heated at reflux for 1.25h under argon. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo* to an oil. The oil was purified by chromatography over silica gel eluting with a gradient of methanol/dichloromethane, pooling fractions which contained the major component (R_f 0.9, methanol/dichloromethane 1:19). The purified material was redissolved in methanol (15ml) and the solution was refluxed for 1h under argon. The reaction mixture was cooled to ambient temperature and concentrated *in vacuo* to a solid which was stirred with diethyl ether (5ml) and filtered to afford the title compound (E2) (0.08g, 0.21mmol, 51%).
- δ_H (d₆-DMSO) 3.32 (4H, br s), 3.55 (4H, br s), 7.35 (1H, d, $J = 6.5\text{Hz}$), 7.63-7.77 (4H, m), 7.86 (1H, d, $J = 7.4\text{Hz}$), 8.10 (2H, m), 9.10 (1H, d, $J = 2.4\text{Hz}$), 9.21 (2H, s), 9.24 (1H, d, $J = 2.4\text{Hz}$).
- Mass Spectrum : C₁₉H₁₇N₃O₂S requires 353; found 354 (MH⁺).


Pharmacological data

Compounds can be tested following the procedures outlined in WO98/27081.

- The compounds of Examples E1-E2 were tested and showed good affinity for the 5-HT₆ receptor, having pK_i values > 8.0 at human cloned 5-HT₆ receptors.

Claims:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R^1 and R^2 independently represent hydrogen or C_{1-6} alkyl or R^1 is linked to R^2 to form a group $(CH_2)_2$, $(CH_2)_3$ or $(CH_2)_4$;

R^3 , R^4 and R^5 independently represent hydrogen, halogen, cyano, $-CF_3$, $-CF_3O$, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkanoyl or a group $-CONR^6R^7$;

R^6 and R^7 independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom;

m represents an integer from 1 to 4, when m is an integer greater than 1, two R^2 groups may instead be linked to form a group CH_2 , $(CH_2)_2$ or $(CH_2)_3$;

n represents an integer from 1 to 3;

p represents 1 or 2;

A represents a group $-Ar^1$ or $-Ar^2Ar^3$;

Ar^1 , Ar^2 and Ar^3 independently represent an aryl group or a heteroaryl group, both of which may be optionally substituted by one or more (eg. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6} alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6} alkoxy, aryl C_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxy C_{1-6} alkyl, C_{3-7} cycloalkyl C_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxy carbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonyl C_{1-6} alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonyl C_{1-6} alkyl, C_{1-6} alkylsulfonamido, C_{1-6} alkylamido, C_{1-6} alkylsulfonamido C_{1-6} alkyl, C_{1-6} alkylamido C_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamido C_{1-6} alkyl, arylcarboxamido C_{1-6} alkyl, aroyl, aroyl C_{1-6} alkyl, aryl C_{1-6} alkanoyl, or a group $CONR^8R^9$ or $SO_2NR^8R^9$, wherein R^8 and R^9

independently represent hydrogen or C_{1-6} alkyl or together may be fused to form a 5- to 7- membered aromatic or non-aromatic heterocyclic ring optionally interrupted by an O or S atom; or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E2 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

5

4. A compound according to claim 1 or claim 2 for use in the treatment of depression, anxiety, obesity and cognitive memory disorders.

10 5. A pharmaceutical composition which comprises a compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.